Valuation : Intellipharmaceutics International Inc.

Market Cap 1.41M 1.21M 1.14M 1.04M 1.94M 134M 1.97M 13.59M 5.23M 68.27M 5.28M 5.17M 217M P/E 2021
-0.69x
P/E 2022 -0.82x
Enterprise Value 3.65M 3.14M 2.97M 2.7M 5.05M 348M 5.1M 35.27M 13.58M 177M 13.7M 13.4M 563M EV / Sales 2021
-
EV / Sales 2022 70.4x
Free-Float
98.24%
Yield 2021 *
-
Yield 2022 -
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0.15
5 years 0
Extreme 1.0E-6
0.3
10 years 0
Extreme 1.0E-6
33.5
Manager TitleAgeSince
Director of Finance/CFO - -
Comptroller/Controller/Auditor - 2007-03-31
Corporate Officer/Principal - 2014-01-31
Director TitleAgeSince
Director/Board Member - 2004-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 33
-0.11%-3.20%+49.61%+91.49% 1,002B
-0.27%-3.22%+50.51%+65.89% 644B
+1.63%-2.57%+21.19%+71.12% 443B
-0.63%-1.06%+28.11%+34.59% 343B
+0.43%-14.61%+9.88%+27.26% 262B
+0.93%-1.82%-1.82%+8.41% 245B
-2.25%-13.63%+36.61%+47.43% 212B
-0.90%-5.09%-15.47%-57.75% 199B
-0.58%-3.21%+25.10%+90.54% 181B
Average -0.17%-4.50%+22.63%+42.11% 352.97B
Weighted average by Cap. -0.06%-4.24%+31.90%+57.11%

Financials

2021 2022
Net sales - 65.73K 56.62K 53.43K 48.65K 90.88K 6.27M 91.86K 635K 245K 3.19M 247K 241K 10.15M
Net income -5.15M -4.43M -4.18M -3.81M -7.11M -491M -7.19M -49.73M -19.15M -250M -19.32M -18.9M -794M -2.89M -2.49M -2.35M -2.14M -4M -276M -4.04M -27.96M -10.76M -140M -10.86M -10.62M -446M
Net Debt 1.15M 987K 931K 848K 1.58M 109M 1.6M 11.07M 4.26M 55.6M 4.3M 4.21M 177M 2.24M 1.93M 1.82M 1.66M 3.1M 214M 3.13M 21.67M 8.34M 109M 8.42M 8.24M 346M
Logo Intellipharmaceutics International Inc.
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company’s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.
Employees
11
  1. Stock Market
  2. Stocks
  3. IPCIQ Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!